Durability of Immunity by Hepatitis B Vaccine in Japanese Health Care Workers Depends on Primary Response Titers and Durations
Overview
Authors
Affiliations
Background: Health care workers (HCWs) are frequently exposed to hepatitis B virus (HBV) infection. The efficacy and safety of immunization with the hepatitis B (HB) vaccine are well recognized, but the durability of immunity and need for booster doses in those with secondary vaccine response failure remains controversial.
Methods: This was a retrospective cohort study performed at Osaka University Hospital, Japan. We examined antibodies against HB surface antigen (anti-HBs) titers annually after immunization for previously non-immunized HCWs. Primary responders were categorized by their sero-positive durations as short responders (those whose anti-HBs titers declined to negative range within 3 years), and long responders (those who retained positive anti-HBs levels for 3 years and more). We re-immunized short responders with either single or 3-dose boosters, the long responders with a single booster when their titers dropped below protective levels, and examined their sero-protection rates over time thereafter.
Results: From 2001 to 2012, data of 264 HCWs with a median age of 25.3 were collected. The rate of anti-HBs positivity after primary vaccination were 93.0% after three doses (n = 229), 54.5% after two doses (n = 11), and 4.2% after a single dose (n = 24). Of 213 primary responders, the anti-HBs levels of 95 participants (44.6%) fell below the protective levels, including 46 short responders and 49 long responders. HCWs with higher initial anti-HBs titers after primary vaccination had significantly longer durations of sero-positivity. For short responders, 3-dose booster vaccination induced a longer duration of anti-HBs positivity compared to a single-dose booster, whereas for long responders, a single-dose booster alone could induce prolonged anti-HBs positivity.
Conclusion: Our preliminary data suggested that it may be useful to differentiate HB vaccine responders based on their primary response durations to maintain protective levels of anti-HBs efficiently. A randomized, prospective, large-scale study is warranted to support our findings.
Farias Junior Y, Souza F, Helioterio M, Araujo T, Pinho P Rev Bras Med Trab. 2024; 21(4):e2022975.
PMID: 39132274 PMC: 11316527. DOI: 10.47626/1679-4435-2022-975.
Senoo-Dogbey V, Anto F, Quansah R, Danso-Appiah A PLoS One. 2024; 19(4):e0298771.
PMID: 38626000 PMC: 11020873. DOI: 10.1371/journal.pone.0298771.
Efua S, Armah D, Delali Adwoa W Vaccine X. 2023; 14:100294.
PMID: 37101844 PMC: 10123245. DOI: 10.1016/j.jvacx.2023.100294.
Hagiya H, Nakano Y, Furukawa M, Sunada N, Hasegawa T, Sakurada Y Sci Rep. 2022; 12(1):20628.
PMID: 36450786 PMC: 9709378. DOI: 10.1038/s41598-022-24464-3.
Yang J, Li Y, Ye J, Wang J, Lu H, Yao X J Inflamm Res. 2022; 15:939-951.
PMID: 35210805 PMC: 8856041. DOI: 10.2147/JIR.S347702.